1 Comparable Efficacy of Curcumin and Proton Pump Inhibitor for Functional

2 Dyspepsia: A Randomized Double-blind Controlled Trial.

3	Pradermchai Kongkam ^{1,2,*} , Wichittra Khongkha ³ *, Chawin Lopimpisuth ¹ , Chisanucha							
4	Chumsri ¹ , Prach Kosarussawadee ¹ , Phanupong Phutrakool ⁴ , Sittichai Khamsai ⁵ , Kittisak							
5	Sawanyawisuth ⁵ , Thanyachai Sura ⁶ , Pochamana Phisalprapa ⁷ , Thanwa Buamahakul ⁸ ,							
6	Sarawut Siwamogsatham ¹ , Jaenjira Angsusing ⁹ , Pratchayanan Poonniam ⁹ , Kulthanit							
7	Wanaratna ⁹ , Monthaka Teerachaisakul ⁹ , Krit Pongpirul ^{1,10,**}							
8								
9	Authors' affiliations:							
10	1. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand							
11	2. King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand							
12	3. Chao Phraya Abhaibhubejhr Hospital, Prachin Buri, Thailand							
13	4. Chula Data Management Center, Research Affairs, Faculty of Medicine,							
14	Chulalongkorn University							
15	5. Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand							
16	6. Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand							
17	7. Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand							
18	8. Ratchaburi Hospital, Ratchaburi, Thailand							
19	9. Department of Thai Traditional and Alternative Medicine, Ministry of Public Health,							
20	Nonthaburi, Thailand							
21	10. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA							
22								
23	*Co-first author, equally contributed to this study							

24	**Correspon	ding Author: Assoc. Prof. Dr. Krit Pongpirul, MD, MPH, PhD. Department of						
25	Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok							
26	10330, Thail	10330, Thailand						
27	Email: docto	rkrit@gmail.com						
28								
29	Word count:	3248						
30								
31	Keywords:	Functional dyspepsia, Omeprazole, Curcumin, Turmeric						
32								
33	Abbreviatio	ns:						
34	AE	Adverse Events						
35	С	Curcumin						
36	C+O	Curcumin+Omeprazole						
37	EPS	Epigastric Pain Syndrome						
38	0	Omeprazole						
39	PDS	Postprandial Distress Syndrome						
40	PPIs	Proton Pump Inhibitors						
41	SAE	Serious Adverse Events						
42	SF-LDQ	Short-Form Leeds Dyspepsia Questionnaire						
43	SODA	Severity of Dyspepsia Assessment (SODA)						
44								
45								

46

ABSTRACT

47 **Objectives**

48 Curcumin has been claimed to have gastrointestinal benefits, including dyspepsia, a common 49 disorder that could be managed in a primary care setting with behavioral and dietary 50 modifications as well as over-the-counter medications. This study aimed to compare the 51 efficacy of curcumin versus omeprazole in improving patient-reported outcomes.

52 Design

Patients with functional dyspepsia were randomized to curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). Patients in the combination group received 2 capsules of 250 mg curcumin 4 times daily and 1 capsule of 20 mg omeprazole once daily for 28 days. The primary outcomes were functional dyspepsia symptoms on days 28 and 56 assessed using the Severity of Dyspepsia Assessment (SODA) scores. Secondary outcomes were the occurrence of adverse events (AEs) and serious adverse events (SAEs).

59 **Results**

A total of 206 enrolled patients were randomly assigned to the three groups, of which 151 completed the study. Demographic data (age 49.7±11.9 years; female 73.4%), clinical characteristics, and baseline dyspepsia scores were comparable between the three groups. SODA scores in each group showed significant improvement on day 28 and day 56 in the pain, non-pain, and satisfaction categories. No significant differences were observed among the three groups and no serious adverse events occurred.

66 Conclusion

67 Curcumin and omeprazole have comparable efficacy for functional dyspepsia with no68 obvious synergistic effect.

70 Key Messages:

71 What is already known:

72	٠	Dyspepsia is one of the most common disorders in which patients usually try
73		behavioral and diet modifications, and over-the-counter drugs before seeing a
74		physician.
75	•	Proton pump inhibitors have been established as an effective treatment for functional
76		dyspepsia.
77	•	Curcumin, an active ingredient in turmeric, is currently used for the treatment of
78		dyspepsia in countries in Southeast Asia.
79	•	However, there is no clinical trial evidence to support the use of curcumin as a first-
80		line treatment.
81	What (this study adds:
82	•	Based on this double-blind, placebo-controlled clinical trial, oral curcumin is safe and
83		well tolerated.
84	•	Patients with functional dyspepsia were treated with curcumin, curcumin plus
85		omeprazole, and omeprazole, which showed a similar significant symptomatic
86		improvement.
87	•	There was no synergistic effect detected between omeprazole and curcumin.
88	How tl	his study might affect research, practice, or policy.
89	•	This study provides a possible additional drug option for patients with functional
90		dyspepsia.
91	•	More clinical trials are required to assess long-term outcomes and adverse events.
92		

93 INTRODUCTION

94 Dyspepsia is a frequently occurring disorder that can be caused by a variety of factors, with 95 no evidence of other structural diseases that exhibit similar symptoms. Although dyspepsia is 96 common, most patients do not schedule an appointment with a doctor to treat this condition. 97 One-quarter of patients with dyspepsia have symptoms that require specific treatment, while 98 the rest do not have the symptoms that define them as functional dyspepsia (1). According to 99 Rome IV criteria, patients diagnosed with functional dyspepsia have postprandial fullness, 100 early satiation, epigastric pain or burning, and no evidence of structural disease (including at upper endoscopy) to explain the symptoms. Postprandial Distress Syndrome (PDS) and 101 102 Epigastric Pain Syndrome (EPS) are two types of functional dyspepsia (2).

103 Most patients with functional dyspepsia in a primary care setting would be treated 104 with behavioral and dietary modifications, as well as over-the-counter medications, before 105 seeing a physician. Over-the-counter proton pump inhibitors (PPIs) are commonly 106 recommended in several countries, whereas patients with persistent symptoms require 107 medical attention for possible Helicobacter pylori infection (3-5). The recent Cochrane 108 systematic review on the use of PPIs for functional dyspepsia showed better overall 109 effectiveness with the number needed to treat 11 (6). However, prolonged use of PPIs 110 demonstrated a potential increased risk of fractures, micronutrient deficiencies, infection, etc. 111 Due to the lack of a higher-quality study, these possible adverse effects remain controversial 112 (7-9).

113 Turmeric, scientifically named *Curcuma longa* L., is a plant that has been used 114 extensively for a long period. The active ingredient of its rhizome, curcumin, is used 115 medically topically and orally. In addition to nourishing creams and cosmetics, curcumin 116 powder capsules have been used for the treatment of dyspepsia and other gastrointestinal 117 problems. Turmeric is one of the herbs that is frequently used to alleviate symptoms similar

to dyspepsia among Thai people and those who live near Thailand. However, few conventional physicians have chosen this herbal medicine as the first drug of choice against functional dyspepsia. This is in part due to a lack of research comparing the efficacy and side effects of curcumin with PPI in the treatment of functional dyspepsia. This study aimed to compare the efficacy of curcumin versus PPI in the treatment of patients with functional dyspepsia in a placebo-controlled double-blind trial.

124

125 **METHODS**

126 Study Design

127 This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial was 128 conducted at the Thai Traditional Medicine Institute and Chao Phraya Abhaibhubejhr 129 Hospital from June 2019 to April 2020. The patients were randomly assigned into three 130 groups: curcumin+omeprazole (C+O), curcumin only (C only), and omeprazole only (O 131 only).

132 **Study Population**

133 Patients who were willing to participate in this trial were evaluated for eligibility: symptoms 134 compatible with functional dyspepsia, between 18 and 70 years, ECOG performance status 0 135 or 1, not taken aspirin or NSAIDs for the past 3 months, not taken curcumin or food that 136 significantly contained curcumin during 4 weeks before the study, no symptoms of irritable 137 bowel syndrome (constipation, diarrhea, and frequent defecation), not taken herbal 138 medication or medication that can affect gastrointestinal symptoms and diseases, and not 139 taking PPIs during the 4 weeks before the study. Patients who were pregnant/breastfeeding; 140 had a curcumin allergy; had gallstones; had ulcers or lumps in their stomach, duodenum, or 141 esophagus; had severe inflammation of the gastric mucosa oesophageal mucosa or intestinal 142 mucosa; had been infected with gastric Helicobacter pylori; had diseases that would hinder

the treatment of functional dyspepsia, or had symptoms or physical signs that are a warning
sign of serious diseases incompatible with functional dyspepsia, were excluded from this
study. All patients underwent gastroscopy to confirm the functional dyspepsia diagnosis.

146 **Randomization and Blinding**

147 Participants were recruited at the Institute of Thai Traditional Medicine, Department of Thai 148 Traditional and Alternative Medicine, Ministry of Public Health, Bangkok, Thailand, and 149 Chao Phraya Abhaibhubejhr Hospital, a tertiary care hospital in Prachinburi, Thailand. The 150 eligible participants were randomly allocated into the three groups using a block 151 randomization of size six at a ratio of 1:1:1. The identification numbers were generated and 152 inserted into the opaque concealed envelope by researchers from the Institute of Thai 153 Traditional Medicine, who were not involved in the care of the volunteers. Clinicians, data 154 collectors, and patients were blinded during this entire process. The randomization 155 identification number was assigned to three groups with the code of each participant and 156 delivered sealed envelopes to the doctor conducting the research in the area.

157 **Recruitment**

Methods for recruiting participants include being a patient under the care of physicians in both institutions, creating electronic media, printed media, promoting flyers, contacting the patient's physician to introduce the researcher to the participants, and publicizing the study in healthcare facilities that provide both conventional and traditional Thai medicine services.

162 Treatment and safety protocol

Each group of enrolled participants was provided with the medications in-person at both sites. The provided medications were packaged in two sizes: large capsules (250 mg of curcumin or placebo), and small capsules (20 mg of omeprazole or placebo). Each participant was instructed to take two large capsules four times a day and one small capsule once a day for 28 days.

168 Any possible side effects could be reported at any time, while patients were formally 169 assessed for possible adverse events on day 28. The following discontinuation criterion was 170 applied: (1) participants were allergic to the medication or unable to take the medication, (2) 171 participants did not follow up on the evaluation of treatment, (3) participants were unable to 172 tolerate the side effects of the medication, (4) pathological examination results of lesions in 173 the esophagus, stomach, or duodenum, show compatibility with certain cancers or tumors, 174 and (5) the endoscopy was unsuccessful. The study termination criteria included (1) serious 175 adverse events (SAEs) of up to 3 percent or occurring in 6 or more volunteers and the matter 176 has been brought to the ethics committee for consideration of the need to discontinue research 177 and (2) doubts or serious ethical errors in the research process.

178 Outcome Measurements

The Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) and the Severity of Dyspepsia Assessment (SODA) were used to measure the extent of the symptoms at the beginning of the study. Later, only SODA was used to observe the changes in severity on day 28 and day 56. Each measurement was performed in the clinics, except for that of day 56 which was conducted by telephone interview.

184 The secondary goal was to evaluate possible adverse events. On day 28, after 185 evaluation, the patients were thoroughly examined by physical examination and interviews to 186 determine whether an undesirable episode occurred during treatment.

187 Sample Size Calculation

The sample size was calculated using a formula to compare the difference in scores by referring to Rosner and Bernard. However, the number of patients per group was 63, due to the possibility of loss, and in the case that participants have another disorder detected after endoscopy, which accounts for about 10%, the authors have therefore specified the sample size to be 70 people in each group.

193 Ethics Consideration

- 194This study was approved by the Ethics Committee for Research in Human Subjects in the195Fields of Thai Traditional and Alternative Medicine (TAMEC No. 11-2561). Participants
- 196 provided their written consent to participate in the study.
- 197 Statistical Analysis
- 198 Descriptive and analytical statistics were performed by using STATA/MP statistical software
- release 15 (StataCorp LLC, College Station, TX). The generalized estimating equation (GEE)
- was used to analyze the primary outcomes at a statistical significance level of 0.05.
- 201

202 **RESULTS**

A total of 241 patients were evaluated for eligibility; of these, 206 met the inclusion criteria and were enrolled and randomized into the three groups. The most common reason for ineligibility was incompatibility with the diagnosis of functional dyspepsia, followed by incorrect age, recent intake of PPI, being pregnant or breastfeeding, current *Helicobacter pylori* infection, and rejection of consent.

Overall, 69, 69, and 68 patients were randomly assigned to the C+O, C, and O groups; of these, 16, 20, and 19 dropped out, respectively. Detailed numbers and explanations for exclusion and dropout are shown in the CONSORT diagram (Figure 1). Baseline demographic and clinical characteristics were similar in the C+O, C, and O groups, of which the summation is given in Table 1.

213

(insert Figure 1 about here)

214

Table 1. Characteristics of the Participants.

		C+O (n=69)	C only (n=69)	O only (n=68)	p-value
De	emographics	(((
-	Female, n (%)	49 (71.01)	50 (72.46)	52 (76.47)	0.756
-	Age (years)	49.54 ± 12.10	49.97 ± 11.96	49.3 ± 11.65	0.946
-	Height (cm)	159.03 ± 8.62	158.8 ± 9.01	159.04 ± 7.56	0.982
-	Weight (kg)	62.13 ± 12.19	62.71 ± 13.38	63.43 ± 12.36	0.835
-	BMI (kg/m ²)	24.44 ± 3.56	24.79 ± 4.43	25.05 ± 4.39	0.693
Vit	tal signs				
-	Pulse rate (beats/min)	78.19 ± 12.01	78.38 ± 8.41	80.82 ± 10.24	0.253
-	Respiratory rate (beats/min)	19.22 ± 1.46	20.03 ± 7.51	19.12 ± 1.40	0.433
-	Body temperature (°C)	36.82 ± 0.37	36.81 ± 0.27	36.85 ± 0.26	0.705
-	Systolic blood pressure	128.36 ± 13.85	129.96 ± 14.37	126.15 ± 16.13	0.321
-	Diastolic blood pressure	77.65 ± 10.96	78.58 ± 9.69	75.96 ± 10.48	0.328
Dy	/spepsia group, n(%)				
-	Postprandial Distress Syndrome (PDS)	43 (63.24)	42 (60.87)	46 (67.65)	0.704
-	Epigastric Pain Syndrome (EPS)	25 (36.76)	27 (39.13)	22 (32.35)	
La	boratory		7404.00	7740.40	
-	White blood cells (cells/mm ³)	6914.48 ± 2107.4	7401.08 ± 2199.63	7710.48 ± 2540.89	0.137
-	Hemoglobin (g/dL)	13.56 ± 2.87	12.9 ± 1.40	12.42 ± 1.87	0.011
-	Hematocrit (%)	40.04 ± 5.15	39.24 ± 3.16	39.12 ± 4.46	0.418
_	Platelet count (cells/mm ³)	260000 ± 57830.24	250000 ± 55400.04	270000 ± 93237.94	0.494
-	AST (SGOT) (U/L)	26.76 ± 9.81	27.90 ± 13.38	25.43 ± 7.89	0.436
-	ALT (SGPT) (U/L)	25.48 ± 16.96	25.64 ± 16.19	28.22 ± 22.11	0.658
-	Total bilirubin (mg/dL)	1.11 ± 2.89	1.07 ± 2.91	1.04 ± 3.45	0.991
-	INR	0.95 ± 0.15	0.99 ± 0.12	0.99 ± 0.1	0.113
_	Creatinine (mg/dL)	0.81 ± 0.38	0.89 ± 0.59	0.91 ± 1.05	0.715
-	Sodium (mmol/L)	139.5 ± 2.1	139.81 ± 2.38	137.59 ± 16.22	0.367
-	Potassium (mmol/L)	3.96 ± 0.43	3.81 ± 0.43	3.92 ± 0.35	0.127
-	Chloride (mmol/L)	104.08 ± 4.37	103.77 ± 3.9	103.5 ± 3.38	0.703
	Total CO ₂ (mmol/L)	24.76 ± 2.93	25.61 ± 6.98	25.08 ± 3.32	0.598

217

218 **Dyspepsia symptom severity**

At baseline, SF-LDQ did not show significant differences, whereas the overall SODA scores (pain intensity, non-pain symptoms, and satisfaction) were comparable between the three groups (Table 2). On day 28, a significant improvement in SODA pain intensity and non-pain symptoms scores was observed in three groups: the pain intensity decreased by -5.41 (95%CI -7.37, -3.45), -6.22 (95%CI -8.20, -4.25), and -6.98 (95%CI -8.95, -5.02) among the groups C+O, C and O, respectively, while the non-pain symptoms decreased by -2.41 (95%CI -3.29,

- 225 -1.52), -2.45 (95%CI -3.34, -156), and -2.55 (95%CI -3.44, -1.66) among the groups C+O, C
- and O, respectively. On the other hand, the SODA satisfaction scores significantly improved
- 227 by 0.86 (95%CI 0.01, 1.72) only in group C.
- 228

229 Table 2. Baseline SF-LDQ and SODA Scores.

Factor	C+O	C only	O only	p-value	
	(n=69)	(n=69)	(n=68)		
SODA					
Pain intensity (2-47)	25.80 ± 3.22	25.14 ± 4.09	26.26 ± 3.74	0.208	
Non-pain symptoms (7-35)	16.14 ± 3.18	15.58 ± 3.21	15.74 ± 2.69	0.530	
Satisfaction (2-23)	11.78 ± 1.98	11.84 ± 1.65	11.68 ± 2.29	0.891	
SF-LDQ					
Method 1 (Sum frequency)	7.90 ± 4.23	7.01 ± 4.06	7.12 ± 3.56	0.360	
Method 2 (Sum severity)	7.97 ± 4.25	6.88 ± 4.14	6.85 ± 3.65	0.182	
Method 3 (Total)	15.87 ± 8.44	13.90 ± 8.16	13.96 ± 7.20	0.258	
Method 4 (Highest frequency)	3.16 ± 1.15	3.20 ± 1.02	3.41 ± 0.80	0.290	
Method 5 (Highest severity)	3.19 ± 1.18	3.19 ± 1.03	3.31 ± 0.87	0.721	

²³⁰

231 The comparison of day 0 with day 56 showed a significant improvement in each 232 category of SODA scores. Also, the comparison of day 28 and day 56 showed positive 233 changes in each category. The exhaustive numbers for each SODA score were available in 234 Table 3. Furthermore, the detailed analysis of the SODA scores on non-pain symptoms 235 divided according to item 7 to item 13 was available in Table 4. Figures 2, 3, and 4 visually 236 demonstrated changes in SODA scores visually based on pain intensity, nonpain symptoms, 237 and satisfaction, respectively. In all, each summary statistics was displayed by their mean and 238 95% confidence intervals.

239

(insert Figure 2, 3, and 4 about here)

Analysis of SODA scores by a GEE did not show significant differences between the C+O group versus the C group, the C+O group versus the O group, and the C group versus the O group (Table 5).

:	SODA Score	Day 0 (95% CI)	Day 28 (95% CI)	Day 56 (95% CI)	p-value	Day 28 – Day 0 (95% Cl)	p-value	Day 56 – Day 28 (95% CI)	p-value	Day 56 – Day 0 (95% Cl)	p-value
Pain int	tensity (2-47)	, , , , , , , , , , , , , , , , , , ,	x x			, , , , , , , , , , , , , , , , , , ,		, <i>t</i>		, , , , , , , , , , , , , , , , , , ,	
0	C+O`´	25.80	20.39	17.57	<0.001	-5.41	<0.001	-2.82	0.007	-8.23	<0.001
		(24.15, 27.45)	(18.63, 22.14)	(15.75, 19.39)		(-7.37, -3.45)		(-4.88, -0.76)		(-10.25, -6.21)	
0	C only	25.14	18.92	<u>)</u> 15.55	<0.001	-6.22	<0.001	-3.37	0.002	-9.59	<0.001
	•	(23.49, 26.8)	(17.15, 20.69)	(13.69, 17.42)		(-8.20, -4.25)		(-5.48, -1.26)		(-11.65, -7.53)	
0	O only	26.26	19.28	15.64	<0.001	-6.98	<0.001	-3.64	0.001	-10.62	<0.001
		(24.6, 27.93)	(17.52, 21.04)	(13.76, 17.52)		(-8.95, -5.02)		(-5.75, -1.52)		(-12.70, -8.54)	
0	p-value	0.642	0.484	0.228		0.491	-	0.914		0.259	-
Non-pa	in symptoms (7-35)										
0	C+O	16.14	13.74	11.50	<0.001	-2.41	<0.001	-2.24	<0.001	-4.65	<0.001
		(15.40, 16.89)	(12.95, 14.53)	(10.68, 12.32)		(-3.29, -1.52)		(-3.17, -1.31)		(-5.56, -3.74)	
0	C only	15.58	13.13	10.81	<0.001	-2.45	<0.001	-2.32	<0.001	-4.77	<0.001
		(14.84, 16.32)	(12.34, 13.93)	(9.98, 11.64)		(-3.34, -1.56)		(-3.27, -1.38)		(-5.69, -3.85)	
0	O only	15.74	13.18	11.15	<0.001	-2.55	<0.001	-2.03	<0.001	-4.59	<0.001
		(14.99, 16.48)	(12.39, 13.98)	(10.29, 12)		(-3.44, -1.66)		(-3, -1.07)		(-5.53, -3.64)	
0	p-value	0.553	0.502	0.514		0.964	-	0.791		0.462	=
Satisfa	ction (2-23)										
0	C+Ò	11.78	12.22	12.69	0.123	0.44	0.309	0.47	0.304	0.90	0.041
		(11.15, 12.41)	(11.54, 12.90)	(11.98, 13.39)		(-0.41, 1.28)		(-0.42, 1.35)		(0.04, 1.77)	
0	C only	<u>11.83</u>	12.70	12.88	0.038	0.86	0.048	0.19	0.689	1.05	0.020
		(11.20, 12.47)	(12.01, 13.38)	(12.16, 13.60)		(0.01, 1.72)		(-0.72, 1.09)		(0.17, 1.93)	
0	O only	11.68	12.41	12.74	0.049	0.73	0.090	0.34	0.468	1.07	0.019
	-	(11.04, 12.31)	(11.73, 13.08)	(12.01, 13.47)		(-0.11, 1.57)		(-0.57, 1.25)		(0.18, 1.96)	
0	p-value	0.941	0.622	0.927		0.680	-	0.921		0.959	-

Table 3. Comparative Changes in SODA Scores among the C+O, C only, and O only groups.

245 C, Curcumin; O, Omeprazole

	SODA Score	Day 0 (95% CI)	Day 28 (95% CI)	Day 56 (95% CI)	p-value	Day 28 – Day 0 (95% CI)	p-value	Day 56 – Day 28 (95% CI)	p-value	Day 56 – Day 0 (95% CI)	p-valu
Non-r	pain symptoms (7-35)										
	Burping/belching										
	⇒ C+O	2.10	1.79	1.51	<0.001	-0.31	0.011	-0.28	0.032	-0.59	<0.00
	010	(1.91, 2.30)	(1.58, 2)	(1.3, 1.73)	20.001	(-0.55, -0.07)	0.011	(-0.53, -0.02)	0.002	(-0.83, -0.34)	~0.00
	Conhy	2.16	1.81	1.57	<0.001	-0.35	0.004	-0.24	0.068	-0.59	<0.00
	o Conly				<0.001		0.004		0.000		<0.00
		(1.96, 2.36)	(1.60, 2.02)	(1.35, 1.79)		(-0.59, -0.11)		(-0.49, 0.02)		(-0.84, -0.34)	
	o O only	2.06	1.80	1.47	<0.001	-0.26	0.036	-0.33	0.011	-0.59	<0.00
		(1.86, 2.26)	(1.59, 2.01)	(1.24, 1.69)		(-0.50, -0.02)		(-0.59, -0.08)		(-0.84, -0.34)	
•	Heartburn										
	• C+O	2.49	1.82	1.29	<0.001	-0.67	<0.001	-0.53	0.001	-1.20	< 0.00
		(2.27, 2.72)	(1.58, 2.06)	(1.04, 1.54)		(-0.96, -0.39)		(-0.83, -0.23)		(-1.50, -0.91)	
	o Conly	2.10	1.54	1.30	<0.001	-0.56	<0.001	-0.25	0.118	-0.80	<0.00
		(1.88, 2.33)	(1.30, 1.79)	(1.04, 1.55)	20.001	(-0.85, -0.27)	20.001	(-0.55, 0.06)	0.110	(-1.10, -0.50)	NO.00
	- O only	2.19	1.43		<0.001		<0.001		0.620	(/ /	<0.00
	o O only			1.36	<0.001	-0.76	<0.001	-0.08	0.620	-0.83	<0.00
		(1.96, 2.42)	(1.19, 1.68)	(1.10, 1.62)		(-1.04, -0.47)		(-0.39, 0.23)		(-1.14, -0.53)	
•	Bloating										
	o C+O	2.72	1.91	1.79	<0.001	-0.81	<0.001	-0.13	0.429	-0.94	<0.00
		(2.48, 2.97)	(1.66, 2.17)	(1.52, 2.06)		(-1.11, -0.51)		(-0.44, 0.19)		(-1.25, -0.63)	
	o Conly	2.72	2.01	1.48	<0.001	-0.72	<0.001	-0.53	0.001	-1.25	<0.00
	e e e,	(2.48, 2.97)	(1.75, 2.27)	(1.21, 1.75)		(-1.02, -0.42)		(-0.85, -0.21)	0.001	(-1.56, -0.93)	
	o O only	2.85	2.12	1.72	<0.001	-0.73	<0.001	-0.40	0.015	-1.13	<0.00
					<0.001		<0.001		0.015		<0.00
		(2.61, 3.1)	(1.86, 2.38)	(1.44, 2)		(-1.04, -0.43)		(-0.72, -0.08)		(-1.45, -0.82)	
	Passing gas										
	o C+O	2.23	1.91	1.57	<0.001	-0.32	0.016	-0.34	0.014	-0.66	<0.00
		(2.04, 2.43)	(1.70, 2.12)	(1.35, 1.79)		(-0.58, -0.06)		(-0.61, -0.07)		(-0.93, -0.39)	
	o Conly	2.01	1.67	1.35	<0.001	-0.35	0.009	-0.32	0.026	-0.66	<0.0
	,	(1.82, 2.21)	(1.46, 1.88)	(1.13, 1.58)		(-0.61, -0.09)		(-0.59, -0.04)		(-0.93, -0.39)	
	o O only	2.01	1.91	1.48	<0.001	-0.11	0.413	-0.42	0.003	-0.53	<0.0
		(1.82, 2.21)	(1.70, 2.12)	(1.26, 1.71)	10.001	(-0.37, 0.15)	0.110	(-0.70, -0.14)	0.000	(-0.80, -0.26)	-0.0
	D =	(1.02, 2.21)	(1.70, 2.12)	(1.20, 1.71)		(-0.57, 0.15)		(-0.70; -0.14)		(-0.00, -0.20)	
	Sour Taste							- - -			
	o C+O	1.75	1.40	1.23	<0.001	-0.36	0.002	-0.17	0.165	-0.52	<0.0
		(1.58, 1.93)	(1.21, 1.58)	(1.04, 1.42)		(-0.58, -0.13)		(-0.40, 0.07)		(-0.75, -0.29)	
	Conly	1.70	1.27	1.05	<0.001	-0.43	<0.001	-0.22	0.068	-0.65	<0.0
		(1.52, 1.87)	(1.08, 1.46)	(0.85, 1.24)		(-0.65, -0.20)		(-0.46, 0.02)		(-0.88, -0.42)	
	o O only	1.71	1.48	1.28	0.002	-0.23	0.049	-0.20	0.111	-0.42	<0.0
		(1.53, 1.88)	(1.29, 1.67)	(1.08, 1.49)		(-0.45, 0)		(-0.44, 0.04)		(-0.66, -0.19)	
	Nausea	(1.00, 1.00)	(1.20, 1.01)	(1.00, 1.10)		(0.10, 0)		(0.11, 0.01)		(0.00, 0.10)	
		4 77	1.00	4 4 4	.0.004	0.44	.0.004	0.00	0.044	0.00	.0.0
	o C+O	1.77	1.36	1.14	<0.001	-0.41	<0.001	-0.22	0.044	-0.63	<0.0
		(1.61, 1.92)	(1.19, 1.53)	(0.96, 1.31)		(-0.61, -0.20)		(-0.44, -0.01)		(-0.84, -0.42)	
	 C only 	1.67	1.22	1.09	<0.001	-0.45	<0.001	-0.13	0.246	-0.58	<0.00
		(1.51, 1.82)	(1.05, 1.39)	(0.91, 1.26)		(-0.66, -0.24)		(-0.35, 0.09)		(-0.80, -0.37)	
	o O only	1.60	1.21	1.13	<0.001	-0.39	<0.001	-0.09	0.453	-0.48	<0.00

Table 4. Comparative Changes in SODA Non-pain Scores among the C+O, C only, and O only groups.

	SODA Score	Day 0 (95% Cl)	Day 28 (95% CI)	Day 56 (95% CI)	p-value	Day 28 – Day 0 (95% Cl)	p-value	Day 56 – Day 28 (95% CI)	p-value	Day 56 – Day 0 (95% Cl)	p-value
•	Bad Breath										
	o C+O	1.65	1.16	1.08	<0.001	-0.50	<0.001	-0.08	0.455	-0.58	<0.001
		(1.50, 1.81)	(0.99, 1.32)	(0.90, 1.25)		(-0.70, -0.30)		(-0.29, 0.13)		(-0.78, -0.37)	
	 C only 	1.54	1.21	1.11	<0.001	-0.33	0.001	-0.10	0.368	-0.42	<0.001
		(1.38, 1.69)	(1.05, 1.38)	(0.94, 1.29)		(-0.53, -0.12)		(-0.31, 0.12)		(-0.63, -0.22)	
	 O only 	1.53	1.27	1.1	<0.001	-0.26	0.012	-0.17	0.117	-0.43	<0.001
		(1.37, 1.68)	(1.11, 1.44)	(0.92, 1.28)		(-0.46, -0.06)		(-0.39, 0.04)		(-0.64, -0.22)	

247 C, Curcumin; O, Omeprazole

248 Table 5. Pairwise Comparison of SODA Scores.

	SODA Scores	C+O vs C only p-value (95% Cl)		C+O vs O only (95% Cl)	p-value C only vs O on (95% Cl)		y p-value	
	Pain intensity (2-47)	-1.23 (-3.09, 0.64)	0.197	-0.70 (-2.57, -1.17)	0.461	0.52 (-1.35, 2.40)	0.584	
	Non-pain symptoms (7-35)	-0.54 (-1.37, 0.28)	0.196	-0.42 (-1.25, 0.40)	0.316	0.12 (-0.71, 0.95)	0.776	
	Satisfaction (2-23)	0.22 (-0.41, 0.86)	0.486	0.03 (-0.60, 0.66)	0.929	-0.20 (-0.83, 0.44)	0.546	
249	С,	Curcumin;				О,		

Omeprazole

250 Adverse events

Adverse events included anxiety, diarrhea, drowsiness, flatulence, headache, and vomiting. In the group C+O, these occurred in two patients (2.90%), including one diarrhea (1.45%), one drowsiness (1.45%), one headache (1.45%), and one vomiting (1.45%). In Group C only, these occurred in three patients (4.35%), including one incident of anxiety (1.45%), one diarrhea (1.45%), one flatulence (1.45%), and one vomiting (1.45%). No serious adverse events took place.

257

258 Discussion

259 Curcumin is a low molecular weight hydrophobic polyphenol extracted from turmeric. 260 Curcumin possesses a wide spectrum of biological properties, including anti-inflammatory, 261 antioxidant, antiproliferative, and antimicrobial properties. Numerous clinical trials have 262 established the pharmacological properties of curcumin. Mechanisms of symptom generation 263 in patients with functional digestive disorders are poorly understood, due to the absence of a 264 mucosal injury that could explain their distressing symptoms (10). Transient receptor potential vanilloid type 1 (TRPV1) receptors have been shown to play a critical role in the 265 266 detection and transmission of somatic and visceral nociceptive neural signals(11), and have 267 been implicated in the induction of symptoms in these diseases. TRPV1 is a multimodal 268 sensory transducer that can be activated by a variety of harmful stimuli including heat, low 269 pH, endogenous lipid derivatives such as anandamide, and exogenous vanilloid-containing 270 substances such as capsaicin (12). In particular, curcumin shares the same vanilloid ring 271 moiety as capsaicin, making TRPV1 a likely target, and it has been shown in animals that 272 curcumin inhibits capsaicin-induced TRPV1 activation competitively (13). Increased TRPV1 273 signaling has been suggested to contribute to visceral hypersensitivity in functional 274 gastrointestinal diseases, including esophageal hypersensitivity(13). Additionally, TRPV1

275 receptors are highly expressed throughout the gastrointestinal tract and enteric nervous 276 system, and there is evidence that curcumin can inhibit gastrointestinal nociception and 277 reverse intestinal hypersensitivity through peripheral terminals. With this mechanism of 278 action in mind, it cannot be ruled out that this molecule may be beneficial in the treatment of 279 patients with functional dyspepsia and irritable bowel syndrome, which are disorders that 280 remain clinically challenging in the presence of currently available medications and whose 281 patients may benefit from curcumin's pharmacological properties on TRPV1 as a novel pain 282 modulator. Curcumin has been clinically studied in patients with inflammatory bowel 283 disease, irritable bowel syndrome, ulcers, Helicobacter pylori infections, and even 284 pancreatitis. Curcumin is effective in the treatment of gastric ulcers, erosions, and dyspepsia 285 (14, 15), with ulcers and erosions reduced or even eradicated after administration of curcumin 286 (3,000 mg/day) administration for up to 12 weeks, while abdominal pain and discomfort were 287 significantly reduced. This explains why in this study we compared curcumin with a PPI as a 288 treatment for functional dyspepsia.

289 Similarly to the findings of the current study, curcumin is safe in numerous human 290 studies, with only minor toxicity associated with this polyphenol(16). Velayudhan et al. also 291 documented the traditional use of curcumin and noted that even a single oral dose of up to 292 8000 mg was not detected in the serum(17). Therefore, curcumin is increasingly being 293 viewed as a biomolecule capable of being administered for an extended period without 294 causing adverse effects(18). After 72 hours, safety was assessed in a dose increase study 295 involving 34 healthy volunteers who received curcumin doses ranging from 500 to 12,000 296 mg. Only seven subjects reported mild disturbances, including headache, skin rash, diarrhea, 297 and yellow stool(19). Another study, which lasted 1-4 months, found that increasing the dose 298 of curcumin from 0.45 to 3.6 g/d resulted in rare cases of nausea and diarrhea, as well as 299 increased alkaline phosphatase and lactate dehydrogenase (20). Some patients treated with

doses as high as 8 g/d for two weeks complained of abdominal pain and bulky size (21). The
findings of the current study confirmed the safety of curcumin compared to PPIs when used
to treat functional dyspepsia.

303 Recently published Cochrane Database of Systematic Reviews demonstrated that PPI 304 was more effective than placebo in the treatment of functional dyspepsia, regardless of the 305 dose or duration of treatment (6, 22). The presence of reflux symptoms or different subtypes 306 of functional dyspepsia had no effect on the effect of PPI over placebo. PPIs may be slightly 307 more effective in alleviating general symptoms of dyspepsia than H2RA and prokinetics. 308 However, several previous studies have demonstrated adverse events associated with long-309 term PPI use (23, 24). Therefore, trials are required that examine the longer-term benefits 310 and harms (at least six to twelve months) benefits and harms of PPI in functional dyspepsia. 311 To expand the treatment options for patients with functional dyspepsia, we decided to 312 compare PPI and curcumin in this study. The findings of the current study indicate that there 313 are no significant adverse events associated with the short-term use of PPI and curcumin.

314 To our knowledge, this is the first study to demonstrate the efficacy of curcumin in 315 functional dyspepsia. Curcumin is effective in all subtypes of functional dyspepsia. Curcumin 316 and omeprazole are both effective for functional dyspepsia and do not appear to have a 317 synergistic effect. Although the most recent Thailand dyspepsia guidelines (2018) (28) 318 recommended that patients with undiagnosed dyspepsia who do not have alarm symptoms 319 receive an empirical trial of PPI for 4-8 weeks as first-line therapy. Prokinetic agents may be 320 used in patients with unexplained dyspepsia who do not improve after empirical PPI therapy. 321 Furthermore, prokinetic agents, tricyclic antidepressants, and cytoprotective agents have been 322 shown to improve symptoms in patients with functional dyspepsia after the failure of PPI 323 therapy. Although this guideline did not specifically mention curcumin as a treatment option

for functional dyspepsia, the new findings from our study may justify considering curcuminin clinical practice.

326 As a multicentre randomized controlled trial, this study is highly reliable. The study's 327 subject is also noteworthy because functional dyspepsia is a prevalent disorder in the general 328 population. The chosen drug is a proton pump inhibitor, widely used, has been approved for 329 over-the-counter use, and is the first-line therapy for patients with functional dyspepsia. The 330 medication chosen as a comparator is curcumin, a popular herbal remedy in the general 331 population. In the context of gastrointestinal disorders, there is no precedent for comparing 332 two drugs in a double-blind randomized controlled trial. The study participants met all 333 criteria and were also diagnosed separately by endoscopy to rule out the presence of 334 symptoms consistent with other diseases. They were also tested for H Pylori and those with 335 infection were isolated.

336 In addition, the research methods are completely bias-free, as the individuals who 337 administered the drugs, the participants who received the drugs, and the individuals who 338 performed the assessment were unaware of the type of medications taken by the participants. 339 The trial was carried out in hospitals frequented by the participants, namely hospitals in other 340 provinces and Thai traditional medicine hospitals. The assessment used standardized 341 questionnaires, and the individuals who conducted it were also certified for accuracy in the 342 assessment. The number of participants was determined statistically accurately using 343 standardized research methods.

The number of participants and the randomization used to assign them to different groups were conducted in a confidential and unbiased manner. All individuals involved in the drug administration process were unaware of the types of drugs distributed or to whom they were distributed. The statistical tests used in this study were conducted using appropriate materials and according to accepted statistical principles.

Two additional follow-up appointments have been scheduled to address the side effects of the study. Blood tests were performed on participants during the second follow-up to assess liver function. No abnormal symptoms were observed after the administration of either of the drugs.

353 The study findings indicated that the required number of participants was reached. 354 However, it was discovered that several participants did not provide follow-up information 355 after medication administration, which is the weakness of the study. However, the number of 356 participants who provided this information was sufficient for statistical analysis and the 357 majority of the participants attended the follow-up. Therefore, it can be deduced from the 358 results that even if the number of participants followed after drug administration increased, 359 the study findings would not be significantly different. Another limitation of this study is the 360 absence of long-term follow-up data for all patients after treatment. This is a question that 361 will require further investigation.

362 The strength of the study is that the findings can be applied to patients with functional 363 dyspepsia who visit their doctor in general clinics or hospitals since the study settings 364 correspond to the daily operations of physicians who already encounter this group of patients. 365 According to the research findings, patients with functional dyspepsia would have additional 366 drug options in addition to proton pump inhibitors alone, with no additional side effects. The 367 study findings can be made completely public. The study was partially funded by government 368 organizations, ensuring that there was no bias in the selection of particular medications. 369 Additionally, this study is the first well-designed randomized controlled trial of curcumin 370 versus PPI in functional dyspepsia. Functional dyspepsia was confirmed by endoscopy and H. 371 *pylori* infection was ruled out. Although we strictly exercised the method to ensure the high 372 integrity of the experiment, this study was subject to limitations, including a small number of 373 patients who were lost to follow-up and a lack of long-term follow-up data.

374	Future studies in this issue will examine the long-term benefit and harms (at least 6-12
375	months) benefit and harms of curcumin in functional dyspepsia; the results of the use of
376	curcumin on demand long-term in functional dyspepsia; and the efficacy of curcumin in other
377	functional gastrointestinal disorders.
378	Conclusion
379	Curcumin and omeprazole have comparable efficacy for functional dyspepsia with no
380	obvious synergistic effect.

382	Fundi	ng statement: This study received financial support from the Department of Thai
383	Traditi	onal and Alternative Medicine, Ministry of Public Health, Nonthaburi, Thailand.
384	Comp	eting interests: The authors declare that they have no competing interests.
385	Autho	r's Contributions:
386	•	Pradermchai Kongkam: Data curation, Writing original draft, Review and Editing
387	•	Wichittra Khongkha: Data curation, Writing original draft, Review and Editing
388	•	Chawin Lopimpisuth: Writing original draft, Review and Editing
389	•	Chisanucha Chumsri: Writing original draft, Review and Editing
390	•	Prach Kosarussawadee: Data curation, Review and Editing
391	•	Phanupong Phutrakool: Data curation, Review and Editing
392	•	Sittichai Khamsai: Data curation, Review and Editing
393	•	Kittisak Sawanyawisuth: Data curation, Review and Editing
394	•	Thanyachai Sura: Data curation, Review and Editing
395	•	Pochamana Phisalprapa: Data curation, Review and Editing
396	•	Thanwa Buamahakul: Data curation, Review and Editing
397	•	Sarawut Siwamogsatham: Data curation, Review and Editing
398	•	Jaenjira Angsusing: Administration, Data curation, Review and Editing
399	•	Pratchayanan Poonniam: Administration, Data curation, Review and Editing
400	•	Kulthanit Wanaratna: Supervision, Data curation, Review and Editing
401	•	Monthaka Teerachaisakul: Supervision, Funding, Data curation, Review and Editing
402	•	Krit Pongpirul: Study Design, Data curation, Formal Analysis, Writing original draft,
403		Review and Editing

404 **Reference**

- 405 1. Bytzer P, Talley NJ. Dyspepsia. Annals of Internal Medicine. 2001;134(9_Part_2):815-22.
- 406 2. Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal
 407 Disorders. Gastroenterology. 2016;150(6):1380-92.
- 408 3. Lacy BE, Talley NJ, Locke GR, 3rd, Bouras EP, DiBaise JK, El-Serag HB, et al. Review article: current
 409 treatment options and management of functional dyspepsia. Aliment Pharmacol Ther.
 410 2012;36(1):3-15.
- 4. Malfertheiner P, J MO, Fischbach W, Layer P, Leodolter A, Stolte M, et al. Helicobacter pylori
 eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther.
 2003;18(6):615-25.
- 5. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353.
- 416 6. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional
 417 dyspepsia. Cochrane Database Syst Rev. 2017;11(11):Cd011194.
- Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk
 of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol.
 2011;106(7):1209-18; quiz 19.
- 421 8. Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging
 422 Concerns. Mayo Clinic Proceedings. 2018;93(2):240-6.
- 423 9. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther
 424 Adv Drug Saf. 2018;10:2042098618809927-.
- 425 10. Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous
 426 subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10(6):371-80.
- 427 11. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut. 2008;57(5):674428 83.
- 429 12. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a
 430 high threshold for noxious heat. Nature. 1999;398(6726):436-41.
- 431 13. Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, et al. Increased TRPV1 gene
 432 expression in esophageal mucosa of patients with non-erosive and erosive reflux disease.
 433 Neurogastroenterol Motil. 2010;22(7):746-51, e219.
- 434 14. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect
 435 of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med
 436 Public Health. 2001;32(1):208-15.
- 437 15. Kositchaiwat C, Kositchaiwat S, Havanondha J. Curcuma longa Linn. in the treatment of gastric
 438 ulcer comparison to liquid antacid: a controlled clinical trial. J Med Assoc Thai. 1993;76(11):601439 5.
- 16. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a
 curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
- 442 17. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a
 443 chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res.
 444 2001;21(4b):2895-900.
- 18. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of
 oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res.
 2004;10(20):6847-54.
- 448 19. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial
 449 of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4(3):354450 64.
- 451 20. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Initial poor quality of life and new onset of
 452 dyspepsia: results from a longitudinal 10-year follow-up study. Gut. 2007;56(3):321-7.
- 453 21. Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr Opin Gastroenterol. 2011;27(6):549-57.

- 454 22. Pittayanon R, Yuan Y, Bollegala NP, Khanna R, Leontiadis GI, Moayyedi P. Prokinetics for
 455 functional dyspepsia. Cochrane Database Syst Rev. 2018;10(10):Cd009431.
- 23. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, et al. Effects of long-term PPI
 treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380-6.
- 458 24. Waldum HL, Fossmark R. Proton pump inhibitors and gastric cancer: a long expected side effect
 459 finally reported also in man. Gut. 2018;67(1):199-200.

461 **Figure Legends**

- 462 Figure 1. CONSORT Diagram.
- 463 Figure 2. Comparative Changes in SODA Pain Scores.
- 464 Figure 3. Comparative Changes in SODA Nonpain Scores.
- 465 Figure 4. Comparative Changes in SODA Satisfaction Scores.







